Vfend Adds Candidiasis Indication; Label Notes QTc Effect Under 10 Msec
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Revised Vfend labeling adding an esophageal candidiasis indication includes results of an FDA-requested study showing that the antifungal increases QTc by less than 10 milliseconds.